Skip to content
Connect Career

MMag. Barbara Eibinger-Miedl Visits ZWT1

Today, we had the honor of welcoming MMag. Barbara Eibinger-Miedl, Styrian State Minister for Science and Research, to the new facilities of CBmed at the ZWT1 Medical Science City Graz. Her visit underscored the importance of our successful Premium Collaboration with Boehringer Ingelheim, which is significantly enhancing our cancer research efforts in Graz.

Eibinger-Miedl remarked, “Our research location and society as a whole benefit from this intensive new partnership in the fight against cancer,” reflecting our commitment to addressing critical health challenges through collaboration.

Thanks to our partnership with Boehringer Ingelheim, we are advancing research and creating job opportunities in Styria—25 positions were added in 2024, with even more anticipated in 2025. Together, we aim to accelerate the journey of new cancer medications to clinical trials, leveraging the extensive resources of Biobank Graz.

During her tour, discussions also emphasized CBmed’s transformation from a COMET K1 Center into an independent entity, which has further strengthened our research capabilities and societal contributions.

We are grateful for the support from regional leaders and look forward to continuing our mission to advance medical research and foster meaningful collaborations.

MMag. Barbara Eibinger-Miedl Visits ZWT1

Today, we had the honor of welcoming MMag. Barbara Eibinger-Miedl, Styrian State Minister for Science and Research, to the new facilities of CBmed at the ZWT1 Medical Science City Graz. Her visit underscored the importance of our successful Premium Collaboration with Boehringer Ingelheim, which is significantly enhancing our cancer research efforts in Graz.

Eibinger-Miedl remarked, “Our research location and society as a whole benefit from this intensive new partnership in the fight against cancer,” reflecting our commitment to addressing critical health challenges through collaboration.

Thanks to our partnership with Boehringer Ingelheim, we are advancing research and creating job opportunities in Styria—25 positions were added in 2024, with even more anticipated in 2025. Together, we aim to accelerate the journey of new cancer medications to clinical trials, leveraging the extensive resources of Biobank Graz.

During her tour, discussions also emphasized CBmed’s transformation from a COMET K1 Center into an independent entity, which has further strengthened our research capabilities and societal contributions.

We are grateful for the support from regional leaders and look forward to continuing our mission to advance medical research and foster meaningful collaborations.

To learn more about our research and its impact, check out the press coverage of the visit and gain deeper insights into how we’re making a difference in Graz and beyond!